Patents by Inventor Igor Vivanco

Igor Vivanco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods to detect tumors using 20P1F12/TMPRSS2 expression
    Patent number: 7981624
    Abstract: Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: July 19, 2011
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas Saffran, Stephen C. Mitchell, Aya Jakobovits, Mary Faris, Igor Vivanco
  • METHODS TO DETECT TUMORS USING 20P1F12/TMPRSS2 EXPRESSION
    Publication number: 20090226921
    Abstract: Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth.
    Type: Application
    Filed: February 19, 2009
    Publication date: September 10, 2009
    Inventors: Daniel E. H. AFAR, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas Saffran, Stephen C. Mitchell, Aya Jakobovits, Mary Faris, Igor Vivanco
  • Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
    Patent number: 7037667
    Abstract: Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-related, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: May 2, 2006
    Assignee: Agensys, Inc.
    Inventors: Daniel E. H. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas Saffran, Stephen C. Mitchell, Aya Jakobovits, Mary Faris, Igor Vivanco
  • Novel tumor antigen useful in diagnosis and therapy of prostate and colon cancer
    Publication number: 20050239122
    Abstract: Compositions for the diagnosis and therapy of prostate and colon cancer, derived from or based on a novel prostate-specific, androgen-regulated, cell membrane associated and secreted serine protease termed 20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire coding sequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) is provided (FIG. 1). Among the compositions provided are antibodies that bind to 20P1F12/TMPRSS2 proteins and polypeptide fragments thereof, including antibodies labeled with a detectable marker or toxin or therapeutic composition. The invention also provides prognostic and diagnostic methods of examining a biological sample for evidence of disregulated cellular growth by comparing the status of 20P1F12/TMPRSS2 in the biological sample to the status of 20P1F12/TMPRSS2 in a corresponding normal sample, wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sample are associated with disregulated cellular growth.
    Type: Application
    Filed: June 7, 2005
    Publication date: October 27, 2005
    Inventors: Daniel Afar, Rene Hubert, Kahan Leong, Arthur Raitano, Douglas Saffran, Stephen Mitchell, Aya Jakobovits, Mary Faris, Igor Vivanco